FDA Approves Lipfendra, First Oral PCSK9 Inhibitor

The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to reduce LDL cholesterol in adults with high cholesterol when used with diet and exercise. This represents a new class of therapy for managing cardiovascular risk.